Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 Into Duchenne Muscular Dystrophy

Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, and Takeda Pharmaceutical Company Limited announced they have extended their existing commercialization partnership for SNT-MC17 (INN: idebenone) in the European Union and Switzerland to cover the compound's second indication of Duchenne Muscular Dystrophy (DMD).
Takeda Pharmaceutical Company Limited